A rapid time to peak serum antibody response following vaccination is particularly important for influenza: the time window between the availability of appropriate antigen and the start of the seasonal epidemic is very short. In this paper, influenza vaccine was delivered to both the epidermis and dermis of mouse skin using densely packed microprojection arrays for vaccination. We found that, after vaccination, around 75% and 90% of the delivered influenza vaccine migrated away from the ear skin within just 2 days and 1 week - respectively. And the time to peak serum antibody response was as early as 2 weeks. This result matches the kinetics achieved by intramuscular injection of liquid vaccine to muscle. Thus, we demonstrate that skin delivery of small vaccine volumes discretely by thousands of densely packed microprojections neither induces delay in kinetics nor interferes with the long-lasting antibody response; compared to conventional intramuscular injection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jconrel.2011.10.026 | DOI Listing |
Arch Biochem Biophys
January 2025
Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150001, China; Heilongjiang Provincial Key Laboratory of Critical Care Medicine, Harbin 150001, China; Central Laboratory of The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. Electronic address:
Background: Ischemia-reperfusion injury (IRI) often results in renal impairment. While the presence of neutrophil extracellular traps (NETs) is consistently observed, their specific impact on IRI is not yet defined. Sivelestat sodium, an inhibitor of neutrophil elastase which is crucial for NET formation, may offer a therapeutic approach to renal IRI, warranting further research.
View Article and Find Full Text PDFGenes (Basel)
December 2024
Sport Sciences Research Centre, Rey Juan Carlos University, 28943 Fuenlabrada, Madrid, Spain.
: Previous studies suggest that there is a genetically determined component of fat oxidation at rest and during exercise. To date, the gene has been proposed as a candidate gene to affect fat oxidation during exercise because of the association of the "at-risk" A allele with different obesity-related factors such as increased body fat, higher appetite and elevated insulin and triglyceride levels. The A allele of the gene may also be linked to obesity through a reduced capacity for fat oxidation during exercise, a topic that remains largely underexplored in the current literature.
View Article and Find Full Text PDFMikrochim Acta
January 2025
Key Laboratory for Palygorskite Science and Applied Technology of Jiangsu Province, National & Local Joint Engineering Research Center for Mineral Salt Deep Utilization, Huaiyin Institute of Technology, Huaian, 223003, P. R. China.
A highly sensitive and selective electrochemical biosensor was developed for the detection of kanamycin using a core-hollow-shell structured peroxidase-mimic nanozyme, CHS-Fe₃O₄@@ZIF-8. The synthesized CHS-FeO@@ZIF-8 was characterized with scanning electron microscopy, transmission electron microscopy, and X-ray photoelectron spectroscopy. It was found that the CHS-FeO@@ZIF-8 exhibits excellent peroxidase-like activity due to its ultra-thin hollow layer.
View Article and Find Full Text PDFToxicol Ind Health
January 2025
Department of Respiratory Diseases, Zhejiang Hospital, Hangzhou, China.
Perfluoroalkyl chemicals are one of the most stable substances in industry and have become ubiquitous contaminants owing to their persistence in the environment. This study enrolled 1,953 participants aged ≥40 years old using data from the National Health and Nutrition Examination Survey (NHANES). We selected four perfluoroalkyl chemicals with a detection frequency of more than 80%, including perfluorohexane sulfonic acid (PFHxS), perfluorononanoic acid (PFNA), perfluorooctanoic acid (PFOA), and perfluorooctane sulfonic acid (PFOS).
View Article and Find Full Text PDFVaccines (Basel)
January 2025
Clinical Development, Takeda Pharmaceuticals International AG, Farman Strasse 11, Opfikon, 8152 Zurich, Switzerland.
Background: Major global economic and health burdens due to norovirus gastroenteritis could be addressed by an effective vaccine.
Methods: In this study, 428 adult recipients of various compositions of the norovirus vaccine candidate, HIL-214, were followed for 5 years, to assess immune responses to its virus-like particle antigens, GI.1 and GII.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!